Innate Pharma 6-K Filing Incorporates Exhibit into F-3
Ticker: IPHYF · Form: 6-K · Filed: Apr 23, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Apr 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, registration-statement
TL;DR
Innate Pharma 6-K: Exhibit 99.1 now part of F-3 registration, excluding CEO quote.
AI Summary
On April 23, 2025, Innate Pharma SA filed a Form 6-K. This report incorporates by reference Exhibit 99.1 into its Form F-3 registration statement (File No. 333-276164), excluding a quote from CEO Jonathan Dickinson. The filing is related to Innate Pharma's principal executive office located at 117 Avenue de Luminy, Marseille, France.
Why It Matters
This filing updates Innate Pharma's registration statement, potentially impacting how investors view the company's ongoing capital-raising or other activities requiring such a statement.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previously disclosed information into a registration statement, with no new material financial or operational information presented.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- Jonathan Dickinson (person) — Chief Executive Officer
- 333-276164 (dollar_amount) — Form F-3 File Number
FAQ
What is the purpose of this Form 6-K filing?
The purpose is to incorporate Exhibit 99.1 into Innate Pharma's registration statement on Form F-3 (File No. 333-276164).
Which specific exhibit is being incorporated by reference?
Exhibit 99.1 to this Report on Form 6-K is being incorporated by reference.
Is the quote from the CEO included in the incorporation?
No, the quotation from Jonathan Dickinson, Chief Executive Officer at Innate Pharma, is explicitly excluded from the incorporation by reference.
What is the address of Innate Pharma's principal executive office?
The principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
What is the Commission File Number for Innate Pharma?
The Commission File Number for Innate Pharma is 001-39084.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 23, 2025 by Jonathan Dickinson regarding Innate Pharma SA (IPHYF).